Next up @JSabari is presenting data on amivantamab in EGFR Exon20ins+ NSCLC. I have participated in the development of amivantamab, though I am not on this particular abstract. Excited to see these data, and Dr Sabari always gives a great presentation! #LCSM #WCLC20
To recap, amivantamab is a bispecific antibody that targets both EGFR and MET. This is thus a very different mechanism of action from the TKI's being developed for EGFR Exon 20ins. Today we will hear updated data on this agent in this population #LCSM #WCLC20
To recap, amivantamab is a bispecific antibody that targets both EGFR and MET. This is thus a very different mechanism of action from the TKI's being developed for EGFR Exon 20ins. Today we will hear updated data on this agent in this population #LCSM #WCLC20
To recap, amivantamab is a bispecific antibody that targets both EGFR and MET. This is thus a very different mechanism of action from the TKI's being developed for EGFR Exon 20ins. Today we will hear updated data on this agent in this population #LCSM #WCLC20
Here is the safety profile of amivantamab - as we have seen before, this agent has a favorable AE profile. Infusion reactions are quite common, but are generally not dangerous. These rarely recur after C1D1. Very few Grade ≥3 AE's. #LCSM #WCLC20
Here is the safety profile of amivantamab - as we have seen before, this agent has a favorable AE profile. Infusion reactions are quite common, but are generally not dangerous. These rarely recur after C1D1. Very few Grade ≥3 AE's. #LCSM #WCLC20
Here is the safety profile of amivantamab - as we have seen before, this agent has a favorable AE profile. Infusion reactions are quite common, but are generally not dangerous. These rarely recur after C1D1. Very few Grade ≥3 AE's. #LCSM #WCLC20
This is impressive, IMO. 40% ORR, including 3 patients having a CR. Activity was seen across a wide range of EGFR Exon 20 ins variants - this is important, as there is substantial heterogeneity in these alterations. #LCSM #WCLC20
This is impressive, IMO. 40% ORR, including 3 patients having a CR. Activity was seen across a wide range of EGFR Exon 20 ins variants - this is important, as there is substantial heterogeneity in these alterations. #LCSM #WCLC20
This is impressive, IMO. 40% ORR, including 3 patients having a CR. Activity was seen across a wide range of EGFR Exon 20 ins variants - this is important, as there is substantial heterogeneity in these alterations. #LCSM #WCLC20
A Ph3 trial is currently underway comparing amivantamab+chemo to chemo for 1L management of EGFR Exon20 ins+ NSCLC #LCSM #WCLC20
You can follow @Jbauml.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.